Skip to main content

European Network of Vaccine Development and Research

Objective

The TRANSVAC infrastructure will accelerate the pharmaceutical and clinical development of promising vaccine candidates by bringing the gap between academic research and clinical trials through carefully managing the advancement of promising vaccine candidates from preclinical animal models to early proof-of-principle studies in humans. Although expertise already exists within Europe spanning different disease types, there is currently very limited coordination between vaccine R&D groups, assay developers and vaccine producers. Unarguably, fragmentation of expertise and facilities has slowed, and in some instances distinctly impeded, the development and validation of promising vaccine candidates. To address these challenges the European vaccine development community needs to establish a collaborative vaccine development infrastructure based on shared visions and goals. The European Vaccine Initiative (EVI) and the Tuberculosis Vaccine Integrated (TBVI) Project have each demonstrated significant success in creating the know-how and infrastructures to enable the advancement of European vaccine development. In order to sustain the momentum generated by EVI and TBVI these successes will be built-upon to create an infrastructure driven by EVI, in which all stakeholders commit to sharing facilities and knowhow on vaccine development. This consortium (TRANSVAC) will comprise major European stakeholders with expertise, resources and facilities for each stage of vaccine development, from the scientific community as well as vaccine developers. Each stakeholder can add to what EVI and TBVI have already established by adding their own expertise to the TRANSVAC long term strategy. TRANSVAC will be the European driving force for vaccine development, and will be accessible to any interested parties. This consortium will initiate a new era in the innovative, harmonised and rapid development of accessible and efficacious vaccines for Europe and the rest of the world.

Call for proposal

FP7-INFRASTRUCTURES-2008-1
See other projects for this call

Funding Scheme

CP-CSA-Infra - Combination of CP and CSA

Coordinator

EUROPEAN VACCINE INITIATIVE EWIV
Address
Vossstrasse 2 Geb 4040
69115 Heidelberg
Germany
Activity type
Research Organisations
EU contribution
€ 2 116 215,72
Administrative Contact
Odile Leroy (Dr.)

Participants (14)

STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER
Netherlands
EU contribution
€ 1 404 380,36
Address
Lange Kleiweg 161
2288 GJ Rijswijk Zh
Activity type
Research Organisations
Administrative Contact
Willem Slingerland (Mr.)
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Germany
EU contribution
€ 577 460,33
Address
Inhoffenstrasse 7
38124 Braunschweig
Activity type
Research Organisations
Administrative Contact
Michael Straetz (Dr.)
VAKZINE PROJEKT MANAGEMENT GMBH
Germany
EU contribution
€ 23 100
Address
Mellendorfer Strasse 9
30625 Hannover
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Leander Grode (Dr.)
LIONEX GMBH
Germany
EU contribution
€ 959 975
Address
Salzdahlumer Strasse 196
38126 Braunschweig
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Mahavir Singh (Prof.)
ID-LELYSTAD, INSTITUUT VOOR DIERHOUDERIJ EN DIERGEZONDHEID B.V.

Participation ended

Netherlands
EU contribution
€ 86 615,36
Address
Edelhertweg 15
8219PH Lelystad
Activity type
Research Organisations
Administrative Contact
Jelle Thole (Dr.)
Public Health England an Executive Agency of the Dept of Health
United Kingdom
Address
Waterloo Road
SE1 8UG London
Activity type
Research Organisations
Administrative Contact
Steve White (Dr.)
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Germany
EU contribution
€ 979 494,97
Address
Hofgartenstrasse 8
80539 Munich
Activity type
Other
Administrative Contact
Stefan H.E. Kaufmann (Prof.)
UNIVERSITAET REGENSBURG
Germany
EU contribution
€ 229 006,82
Address
Universitatsstrasse 31
93053 Regensburg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Christian Blomeyer (Dr.)
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER
United Kingdom
EU contribution
€ 339 000
Address
Keppel Street
WC1E 7HT London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Penny Ireland (Ms.)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU contribution
€ 900 495
Address
Wellington Square University Offices
OX1 2JD Oxford
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gary Strickland (Mr.)
UNIVERSITE DE LAUSANNE
Switzerland
EU contribution
€ 656 775,56
Address
Quartier Unil-centre Bâtiment Unicentre
1015 Lausanne
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gerard Mareine (Mr.)
STICHTING TUBERCULOSIS VACCINE INITIATIVE
Netherlands
EU contribution
€ 85 107,28
Address
Runderweg 6
8219 PH Lelystad
Activity type
Other
Administrative Contact
Jelle Thole (Dr.)
STICHTING WAGENINGEN RESEARCH
Netherlands
EU contribution
€ 586 018,06
Address
Droevendaalsesteeg 4
6708 PB Wageningen
Activity type
Research Organisations
Administrative Contact
Norbert Stockhofe (Dr.)
Department of Health
United Kingdom
EU contribution
€ 956 354,54
Address
Quarry House, Quarry Hill
LS2 7UE Leeds
Activity type
Research Organisations
Administrative Contact
Cathy Rowe (Mrs.)